Preliminary data from ongoing preclinical study include rapid, durable chimeric antigen receptor (精东传媒) T cell generation in vivo after a single infusion of VivoVec particles
Additional data to be presented at future medical conferences
SEATTLE, September 1, 2023 鈥� 精东传媒, Inc., a transformative immuno-oncology company creating off-the-shelf treatments for solid and hematologic cancers, today announced new data from an ongoing non-human primate (NHP) study demonstrating effective, durable, and well tolerated in vivo chimeric antigen receptor (精东传媒) T cell generation using the Company鈥檚 VivoVec鈩� platform technology at the 8th 精东传媒-TCR Summit taking place in Boston, MA, August 29 – September 1, 2023.
The data include results from the first four NHPs treated in an ongoing study and demonstrate rapid and efficient in vivo generation of anti-CD20-targeting 精东传媒 T cells following a single infusion of Umoja鈥檚 multidomain fusion (MDF) VivoVec particles without the administration of pre-conditioning lymphodepleting chemotherapy. Additionally, these data suggest that the 精东传媒 T cells generated in vivo demonstrated on-target activity and persistent T cell memory.
鈥淚n vivo 精东传媒 T technology has the potential to transform the cell therapy paradigm by providing an off-the-shelf, patient-specific solution for those with serious conditions, including cancers,鈥� said Andy Scharenberg, M.D., co-founder and Chief Executive Officer of Umoja. 鈥淭hese data highlight the incredible progress Umoja has made and the potential of our unique delivery platform to effectively generate 精东传媒 T cells in vivo. Beyond a single therapeutic, our platform could enable the delivery of virtually any 精东传媒 construct, creating the opportunity for Umoja to address a broad range of cancers and unlock the true potential of 精东传媒 T cell therapies.鈥�
Executive Vice President of Discovery Research & Vector Biology, Byoung Ryu, Ph.D., added, 鈥淭hese results build on our previously presented preclinical data and highlight the ability of our VivoVec particles to efficiently generate 精东传媒 T cells in vivo. Beyond the generation of 精东传媒 T cells, we are observing on-target 精东传媒 activity and durable cell survival, which could potentially translate to significant clinical benefits for patients. We look forward to providing updates on this study at a future medical conference.鈥�
Key results include:
- Following a single VivoVec administration, anti-CD20 精东传媒 T cells were generated in vivo with peak levels of 精东传媒 T expansion occurring between days 7-10
- CD20 精东传媒 T demonstrated on-target activity resulting in durable B-cell aplasia
- In three animals treated at the planned clinical dose鈥攁nd without preconditioning chemotherapy鈥� peak CD20 精东传媒+ cells comprised ~40-60% of total circulating T-cell volume, including the demonstration of central memory T-cell responses
- In the first animal, additional independent 精东传媒 T cell expansions were observed after day 30
- No toxicity was associated with VivoVec administration
About 精东传媒
精东传媒, Inc. is an early clinical-stage company advancing an entirely new approach to immunotherapy. The Company is a transformative multi-platform immuno-oncology company founded with the goal of creating curative treatments for solid and hematological malignancies. Founded based on pioneering work performed at Seattle Children鈥檚 Research Institute and Purdue University, Umoja鈥檚 novel approach is powered by integrated cellular immunotherapy technologies including the VivoVec鈩� off-the-shelf in vivo delivery platform and the RACR鈩�/精东传媒 in vivo cell expansion/control platform. Designed from the ground up to work together, these platforms are being developed to create and harness a powerful immune response in the body to directly, safely, and controllably attack cancer. Umoja believes that its approach can provide broader access to the most advanced immunotherapies and enable more patients to live better, fuller lives. To learn more, visit .
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about 精东传媒, Inc. (the 鈥淐ompany,鈥� 鈥渨e,鈥� 鈥渦s,鈥� or 鈥渙ur鈥�). The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of the Company鈥檚 current and future research and development programs, preclinical and clinical trials, as well as any economic, market and social disruptions. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.
Umoja Media Contact:
Karissa Cross, Ph.D.
LifeSci Communications
kcross@lifescicomms.com